Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jinxin Fertility Group Limited (1951.HK)
Chengdu, CN
Jinxin Fertility Group Limited is an investment holding company that specializes in providing assisted reproductive services (ARS) across both China and the United States. Its core offerings primarily include two types of treatment: artificial insemination, which can be performed using either the husband's or a donor's sperm, and advanced in vitro fertilization (IVF) technologies, ranging from conventional IVF with embryo transfer to IVF utilizing intracytoplasmic sperm injection (ICSI). To complement its ARS treatments, the company also furnishes a range of supportive services such as nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Beyond fertility-specific care, Jinxin Fertility Group extends its operations to include management services, general medical care encompassing gynecology, urology, and internal medicine, as well as ambulatory surgery center facilities and other ancillary medical services. Furthermore, the company conducts pre-implantation genetic screening tests. Its business scope also diversifies into investment management, management consulting, and real estate development and operation. Jinxin Fertility Group Limited was established in 2003 and has its corporate headquarters located in Chengdu, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.70% | -0.88% | -6.28% | -10.40% | -6.28% | -5.88% | -20.28% | -45.23% | -89.98% | -75.86% | -75.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 8 | +1 |
| Hold | 1 | 0 |
| Sell | 2 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%-8.2% Q4'25: -8.1% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%-450.0% Q4'25: -28.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+13.4% Q4'25: +9.3% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%+7.7% Q4'25: +8.4% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%+1.8% Q4'25: +2.4% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%+0.9% Q4'25: -27.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×5.49× Q4'25: 2.53× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 9 EPS Ana. |
Dec 2027 13 Rev. Ana. 9 EPS Ana. |
Dec 2028 10 Rev. Ana. 8 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.65B
est: 1.71B (-3.4%)
|
1.43B
est: 1.42B (+0.3%)
|
1.84B
est: 1.78B (+3.3%)
|
2.36B
est: 2.31B (+2.4%)
|
2.79B
est: 2.70B (+3.4%)
|
2.81B
est: 2.98B (-5.6%)
|
2.58B
est: 2.66B (-3.1%)
|
2.96B
2.89B – 3.06B
+11.2% YoY
|
3.20B
3.04B – 3.42B
+8.3% YoY
|
3.47B
3.34B – 3.65B
+8.2% YoY
|
| EBITDA |
642.53M
est: 401.73M (+59.9%)
|
331.91M
est: 531.86M (-37.6%)
|
494.08M
est: 660.96M (-25.2%)
|
476.22M
est: 855.06M (-44.3%)
|
682.02M
est: 621.68M (+9.7%)
|
645.06M
est: 683.16M (-5.6%)
|
538.60M
est: 613.91M (-12.3%)
|
682.43M
666.57M – 706.41M
+11.2% YoY
|
738.85M
700.49M – 789.31M
+8.3% YoY
|
799.77M
769.25M – 841.68M
+8.2% YoY
|
| EBIT |
529.98M
est: 279.47M (+89.6%)
|
237.68M
est: 463.02M (-48.7%)
|
371.39M
est: 575.40M (-35.5%)
|
285.37M
est: 744.38M (-61.7%)
|
480.47M
est: 392.98M (+22.3%)
|
441.58M
est: 1.21B (-63.4%)
|
197.93M
est: 388.06M (-49.0%)
|
431.38M
421.35M – 446.54M
+11.2% YoY
|
467.04M
442.79M – 498.93M
+8.3% YoY
|
505.55M
486.25M – 532.04M
+8.2% YoY
|
| Net Income |
409.62M
est: 546.47M (-25.0%)
|
251.62M
est: 340.37M (-26.1%)
|
339.90M
est: 422.99M (-19.6%)
|
121.12M
est: 142.78M (-15.2%)
|
344.72M
est: 320.47M (+7.6%)
|
283.10M
est: -863.40M (+132.8%)
|
-950.88M
est: -876.77M (-8.5%)
|
159.47M
146.96M – 293.90M
+118.2% YoY
|
224.32M
185.52M – 366.63M
+40.7% YoY
|
304.96M
289.13M – 627.84M
+35.9% YoY
|
| SGA |
273.51M
est: 395.49M (-30.8%)
|
316.62M
est: 216.34M (+46.4%)
|
389.45M
est: 268.85M (+44.9%)
|
610.29M
est: 347.81M (+75.5%)
|
673.23M
est: 630.51M (+6.8%)
|
633.18M
est: 692.86M (-8.6%)
|
600.40M
est: 622.63M (-3.6%)
|
692.13M
676.03M – 716.45M
+11.2% YoY
|
749.34M
710.44M – 800.52M
+8.3% YoY
|
811.13M
780.17M – 853.63M
+8.2% YoY
|
| EPS |
0.19
est: 0.20 (-5.5%)
|
0.10
est: 0.14 (-29.4%)
|
0.14
est: 0.14 (-3.2%)
|
0.05
est: 0.15 (-67.4%)
|
0.12
est: 0.12 (+3.6%)
|
0.10
est: 0.16 (-37.7%)
|
-0.35
est: -0.35 (-1.0%)
|
0.08
0.05 – 0.11
+123.7% YoY
|
0.11
0.07 – 0.13
+33.3% YoY
|
0.15
0.11 – 0.23
+34.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-19 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-18 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-15 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.39% | 250.1K | 0.59% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.06% | 68.6K | 0.42% |
| 3 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.05% | 36.0K | 0.74% |
| 4 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.04% | 285.8K | 0.65% |
| 5 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.04% | 125.4K | 0.74% |
| 6 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 121.5K | 0.72% |
| 7 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.03% | 163.5K | 0.55% |
| 8 | State Street SPDR S&P China ETF GXC | 0.02% | 87.7K | 0.59% |
| 9 | Avantis Emerging Markets Equity ETF AVEM | 0.02% | 4.89M | 0.33% |
| 10 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.02% | 110.4K | 0.44% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rong Lyu | Co-CEO & Executive Director | 4M | female |
| Yang Dong | Chief Executive Officer, Acting Chief Financial Officer & Executive Director | 2M | male |
| Lihong Geng | Chief Medical Quality Control Officer & Executive Director | 2M | — |
| Hongmei Duan | Chief Operating Officer | — | female |
| Man Nar Chung | Company Secretary | — | female |
| Yuan Li | Chief Medical Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1951.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
